Shares of Cytokinetics Inc (CYTK) surged 5.01% in pre-market trading on Tuesday, following the announcement of positive topline results from its Maple-HCM trial for aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM).

The company reported that the Maple-HCM study met its primary endpoint, demonstrating a favorable safety profile for aficamten compared to metoprolol, a commonly used beta-blocker for HCM treatment. This positive outcome could potentially position aficamten as a promising alternative for HCM patients.

Investors are likely encouraged by these results, especially considering that aficamten is currently under FDA review with a PDUFA date set for December 26, 2025. The positive trial results may bolster the drug's chances for approval, potentially opening up a significant market opportunity for Cytokinetics in the treatment of HCM. As the market digests this news, the stock's movement reflects growing optimism about the company's future prospects in the cardiovascular disease space.